Scilex Holding (SCLX) Cash from Investing Activities (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Cash from Investing Activities of -$9.2 million for Q1 2026, down 2218.99% year-over-year from $432282.0 in Q1 2025, and down 291.47% quarter-over-quarter from $4.8 million in Q4 2025.
Scilex Holding (SCLX) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Scilex Holding's Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$9.2 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 2218.99% year-over-year to -$9.2 million; the TTM figure through Mar 2026 stood at -$4.7 million (down 60.31% YoY), while the FY2025 annual figure was $4.1 million, up 252.67% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$9.2 million, down from $4.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $4.8 million in Q4 2025, with the low at -$9.2 million in Q1 2026.
- The 5-year median for Cash from Investing Activities is -$155000.0 (2023), against an average of -$676533.3.
- The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities surged 2553.33% in 2025, then tumbled 2218.99% in 2026.
- Scilex Holding's Cash from Investing Activities stood at -$7000.0 in 2022, then slumped by 2285.71% to -$167000.0 in 2023, then declined by 16.77% to -$195000.0 in 2024, then soared by 2553.33% to $4.8 million in 2025, then tumbled by 291.47% to -$9.2 million in 2026.
- Business Quant data shows SCLX's Cash from Investing Activities at -$9.2 million in Q1 2026, $4.8 million in Q4 2025, and -$152000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -2.91 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -569.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.35 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.11 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 8.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.16 Mn |
| Mar 31, 2026 | -9.16 Mn |
| Dec 31, 2025 | 4.78 Mn |
| Dec 31, 2025 | 4.78 Mn |
| Sep 30, 2025 | -152,000.00 |
| Sep 30, 2025 | -152,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Dec 31, 2024 | -195,000.00 |
| Dec 31, 2024 | -195,000.00 |
| Sep 30, 2024 | -2.18 Mn |
| Sep 30, 2024 | -2.18 Mn |
| Jun 30, 2024 | -150,000.00 |
| Jun 30, 2024 | -150,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Dec 31, 2023 | -167,000.00 |
| Dec 31, 2023 | -167,000.00 |